The Second Clinical Medical College, Zhejiang Chinese Medicine University, 310053 Hangzhou, Zhejiang, China.
Department of Neurology, Zhejiang Hospital, 310025 Hangzhou, Zhejiang, China.
J Integr Neurosci. 2024 Aug 12;23(8):143. doi: 10.31083/j.jin2308143.
Alzheimer's disease (AD) is recognized as the leading cause of dementia, imposing a significant economic toll on society. Despite the emergence of novel therapeutic approaches for AD, their efficacy and safety mandates further validation through rigorous clinical trials. In this context, hypertension (HTN) has garnered considerable attention as an amendable risk factor for AD. Research indicates that hypertension during midlife is associated with an elevated risk of AD in later years, influencing both the onset and progression of the disease. Nevertheless, the relationship between AD and hypertension in the later stages of life remains a subject of debate. Moreover, the consequences of blood pressure reduction on cognitive function, along with the optimal pharmacological interventions and therapeutic thresholds for hypertension, have emerged as pivotal areas of inquiry. This review synthesizes findings on epidemiology, neuroimaging, and biomarkers, and the effects of antihypertensive medications to elucidate the link between hypertension and cognitive performance. We particularly investigate how hypertension and AD are related by plasma sulfide dysregulation, offering possible indicators for future diagnosis and therapy.
阿尔茨海默病(AD)是公认的痴呆症主要病因,给社会带来了巨大的经济负担。尽管针对 AD 出现了新的治疗方法,但仍需要通过严格的临床试验进一步验证其疗效和安全性。在这种情况下,高血压(HTN)作为 AD 的可纠正的风险因素受到了极大关注。研究表明,中年时期的高血压与晚年 AD 风险升高有关,影响疾病的发生和进展。然而,AD 与生命后期高血压之间的关系仍然存在争议。此外,血压降低对认知功能的影响,以及降压的最佳药物干预和治疗阈值,已成为重要的研究领域。本综述综合了流行病学、神经影像学和生物标志物方面的研究结果,以及降压药物的作用,以阐明高血压与认知表现之间的联系。我们特别研究了血浆硫化物失调如何使高血压和 AD 相关,为未来的诊断和治疗提供了可能的指标。